{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Salinero AE"],"funding":["American Heart Association","NIA NIH HHS","American Heart Association-American Stroke Association","NIA","BrightFocus Foundation","NINDS NIH HHS","Alzheimer's Association","NINDS"],"pagination":["105594"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11330726"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["164"],"pubmed_abstract":["Menopause is an endocrine shift leading to increased vulnerability for cognitive impairment and dementia risk factors, in part due to loss of neuroprotective circulating estrogens. Systemic replacement of estrogen post-menopause has limitations, including risk for estrogen-sensitive cancers. A promising therapeutic approach therefore might be to deliver estrogen only to the brain. We examined whether we could enhance cognitive performance by delivering estrogen exclusively to the brain in ovariectomized mice (a surgical menopause model). We treated mice with the prodrug 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED), which can be administered systemically but is converted to 17β-estradiol only in the brain. Young and middle-aged C57BL/6 J mice received ovariectomy and subcutaneous implant co"],"journal":["Hormones and behavior"],"pubmed_title":["Treatment with brain specific estrogen prodrug ameliorates cognitive effects of surgical menopause in mice."],"pmcid":["PMC11330726"],"funding_grant_id":["U01 AG072464","R01 NS110749","AARG-21-849204","U01AG072464","908878","23AARGD-1026458","A2022001F"],"pubmed_authors":["Thrasher CA","Zuloaga KL","Zuloaga DG","Smith RM","Belanger KM","Salinero AE","Kelly RD","Abi-Ghanem C","Stephens SBZ","Hatcher KM","Shamlian V","Sura A","NyBlom V","Kyaw NR","Gannon OJ","Venkataganesh H"],"additional_accession":[]},"is_claimable":false,"name":"Treatment with brain specific estrogen prodrug ameliorates cognitive effects of surgical menopause in mice.","description":"Menopause is an endocrine shift leading to increased vulnerability for cognitive impairment and dementia risk factors, in part due to loss of neuroprotective circulating estrogens. Systemic replacement of estrogen post-menopause has limitations, including risk for estrogen-sensitive cancers. A promising therapeutic approach therefore might be to deliver estrogen only to the brain. We examined whether we could enhance cognitive performance by delivering estrogen exclusively to the brain in ovariectomized mice (a surgical menopause model). We treated mice with the prodrug 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED), which can be administered systemically but is converted to 17β-estradiol only in the brain. Young and middle-aged C57BL/6 J mice received ovariectomy and subcutaneous implant co","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-08-16T03:06:55.375Z","creation":"2025-08-16T03:06:55.375Z"},"accession":"S-EPMC11330726","cross_references":{"pubmed":["38917776"],"doi":["10.1016/j.yhbeh.2024.105594"]}}